Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

This study is testing a new type of cancer treatment for advanced pancreatic cancer using specially engineered immune cells called CAR-NK cells. These cells are designed to recognize and attack cancer cells by targeting specific proteins on their surface. This is an early-phase study to see whether the treatment is safe and shows signs of working. **You may be eligible if...** - You are aged 18–75 and have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) - Your cancer cannot be surgically removed and has progressed despite at least one previous treatment - Your tumor tests positive for certain proteins (MSLN, MUC1, or CLDN18.2) that the therapy targets - You are in good enough physical condition to participate (ECOG 0–1) - You have adequate blood counts, liver, and kidney function - Your life expectancy is at least 12 weeks **You may NOT be eligible if...** - Your cancer has spread to the brain - You have an active, uncontrolled infection including HIV, hepatitis B, or hepatitis C - You have had an organ or stem cell transplant - You received a similar gene-modified cell therapy within the past 6 months Talk to your doctor to see if this trial is right for you.